Spots Global Cancer Trial Database for Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma
Official Title: A Phase II Trial of Idelalisib in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Study ID: NCT03576443
Conditions
Interventions
Study Description
Brief Summary: Based on the high response rate in heavily pretreated patients with indolent B-cell lymphomas, among which it is likely that many have undetected transformed disease, the investigators hypothesize that idelalisib may also be active in relapsed DLBCL, particularly of the GCB subtype. Possibly, the efficacy may be related to the presence of specific mutations within the B-cell receptor pathway.
Detailed Description:
Keywords
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Aarhus University Hospital, Aarhus C, , Denmark
Odense University Hospital, Odense, , Denmark
Halmstad County Hospital, Halmstad, , Sweden
Linkoping University Hospital, Linköping, , Sweden
Skane University Hospital, Lund, , Sweden
Karolinska University Hospital, Stockholm, , Sweden
Contact Details
Name: Mats Jerkeman
Affiliation: Department of Oncology Skåne University Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
